...
search icon
incy-img

Incyte Corporation, Common Stock

INCY

NSQ

$58.21

+$0.48

(0.83%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$11.01B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
388.0667
Volume info-icon
This is the total number of shares traded during the most recent trading day.
0
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.90
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$50.35 L
$83.95 H
$58.21

About Incyte Corporation, Common Stock

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameINCYSectorS&P500
1-Week Return5.51%0.44%0.24%
1-Month Return-6.13%-7.69%-7.32%
3-Month Return-19.07%-3.35%-12.05%
6-Month Return-12.37%-11.09%-9.73%
1-Year Return10.41%-2.13%5.05%
3-Year Return-27.54%-1.18%20.03%
5-Year Return-41.79%34.44%83.31%
10-Year Return-42.74%84.87%153.54%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue2.67B2.99B3.39B3.70B4.24B[{"date":"2020-12-31","value":62.88,"profit":true},{"date":"2021-12-31","value":70.41,"profit":true},{"date":"2022-12-31","value":80.04,"profit":true},{"date":"2023-12-31","value":87.14,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue131.33M150.99M207.00M255.00M312.07M[{"date":"2020-12-31","value":42.08,"profit":true},{"date":"2021-12-31","value":48.38,"profit":true},{"date":"2022-12-31","value":66.33,"profit":true},{"date":"2023-12-31","value":81.71,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit2.54B2.84B3.19B3.44B3.93B[{"date":"2020-12-31","value":64.53,"profit":true},{"date":"2021-12-31","value":72.16,"profit":true},{"date":"2022-12-31","value":81.13,"profit":true},{"date":"2023-12-31","value":87.57,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin95.08%94.94%93.90%93.10%92.64%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":99.86,"profit":true},{"date":"2022-12-31","value":98.77,"profit":true},{"date":"2023-12-31","value":97.92,"profit":true},{"date":"2024-12-31","value":97.44,"profit":true}]
Operating Expenses2.78B2.23B2.60B2.82B3.87B[{"date":"2020-12-31","value":71.76,"profit":true},{"date":"2021-12-31","value":57.78,"profit":true},{"date":"2022-12-31","value":67.12,"profit":true},{"date":"2023-12-31","value":72.91,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(240.29M)585.78M579.44M620.52M61.37M[{"date":"2020-12-31","value":-38.72,"profit":false},{"date":"2021-12-31","value":94.4,"profit":true},{"date":"2022-12-31","value":93.38,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":9.89,"profit":true}]
Total Non-Operating Income/Expense29.28M(17.24M)(52.99M)319.89M381.69M[{"date":"2020-12-31","value":7.67,"profit":true},{"date":"2021-12-31","value":-4.52,"profit":false},{"date":"2022-12-31","value":-13.88,"profit":false},{"date":"2023-12-31","value":83.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(232.22M)570.44M529.12M834.22M316.63M[{"date":"2020-12-31","value":-27.84,"profit":false},{"date":"2021-12-31","value":68.38,"profit":true},{"date":"2022-12-31","value":63.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":37.96,"profit":true}]
Income Taxes63.48M(378.14M)188.46M236.62M284.01M[{"date":"2020-12-31","value":22.35,"profit":true},{"date":"2021-12-31","value":-133.14,"profit":false},{"date":"2022-12-31","value":66.35,"profit":true},{"date":"2023-12-31","value":83.31,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(295.70M)948.58M340.66M597.60M32.62M[{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":63,"profit":true},{"date":"2024-12-31","value":3.44,"profit":true}]
Income From Continuous Operations(295.70M)948.58M340.66M424.98M32.62M[{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":44.8,"profit":true},{"date":"2024-12-31","value":3.44,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(295.70M)948.58M340.66M597.60M32.62M[{"date":"2020-12-31","value":-31.17,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":35.91,"profit":true},{"date":"2023-12-31","value":63,"profit":true},{"date":"2024-12-31","value":3.44,"profit":true}]
EPS (Diluted)(0.46)2.752.783.521.32[{"date":"2020-12-31","value":-13.07,"profit":false},{"date":"2021-12-31","value":78.13,"profit":true},{"date":"2022-12-31","value":78.98,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":37.5,"profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

INCY
Cash Ratio 1.31
Current Ratio 1.97
Quick Ratio 1.94

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

INCY
ROA (LTM) 0.86%
ROE (LTM) 0.75%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

INCY
Debt Ratio Lower is generally better. Negative is bad. 0.37
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.63

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

INCY
Trailing PE 388.07
Forward PE 9.62
P/S (TTM) 2.66
P/B 3.27
Price/FCF 31
EV/R 2.16
EV/Ebitda 22.42
PEG 0.37

FAQs

What is Incyte Corporation share price today?

Incyte Corporation (INCY) share price today is $58.21

Can Indians buy Incyte Corporation shares?

Yes, Indians can buy shares of Incyte Corporation (INCY) on Vested. To buy Incyte Corporation from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in INCY stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Incyte Corporation be purchased?

Yes, you can purchase fractional shares of Incyte Corporation (INCY) via the Vested app. You can start investing in Incyte Corporation (INCY) with a minimum investment of $1.

How to invest in Incyte Corporation shares from India?

You can invest in shares of Incyte Corporation (INCY) via Vested in three simple steps:

  • Click on Sign Up or Invest in INCY stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Incyte Corporation shares
What is Incyte Corporation 52-week high and low stock price?

The 52-week high price of Incyte Corporation (INCY) is $83.95. The 52-week low price of Incyte Corporation (INCY) is $50.35.

What is Incyte Corporation price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Incyte Corporation (INCY) is 388.0667

What is Incyte Corporation price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Incyte Corporation (INCY) is 3.27

What is the Market Cap of Incyte Corporation?

The market capitalization of Incyte Corporation (INCY) is $11.01B

What is Incyte Corporation’s stock symbol?

The stock symbol (or ticker) of Incyte Corporation is INCY

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top